source
- Wave aims for monthly dosing with RNA editing treatment for AATDWave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. Peo…Endpoints · 2mo ago↗ source
- Full-Life Technologies raises $150M; Quince's reboot with pulmonary drugPlus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round an…Endpoints · 2mo ago↗ source
- STAT+: Dexcom CEO hints at future uses for CGMIn this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.STAT